Reaction Details  Report a problem with these data
Cell Reactant:
HIV-1 Protease Mutant (V82F/I84V)
Syringe Reactant:
BDBM517
Meas. Tech.:
Isothermal Titration Calorimetry
Entry Date.:
2004-04-20
ΔG°:
-9.2±n/a (kcal/mole)
pH:
5.0000±n/a
Temperature:
298.1500±n/a (K)
ΔH° :
5.9±0.2 (kJ/mole)
ΔHobs :
5.84±n/a (kJ/mole)
Corrected for ΔHioniz:
not known
Protons Released:
0.5000
ΔCp :
-0.58±0.06 (kJ/mole)
ΔS° :
0.05±n/a (kJ/mole-K)
Citation
 Todd, MJ; Luque, I; Velázquez-Campoy, A; Freire, E Thermodynamic basis of resistance to HIV-1 protease inhibition: calorimetric analysis of the V82F/I84V active site resistant mutant. Biochemistry 39:11876-83 (2000) [PubMed]  Article
Cell React
Source:
mutations at position 82 and 84 were introduced using an in vitro site-directed mutagenesis kit, mutant protease was expressed in BL21/DE3
Purity:
99%
Prep. Method:
HIV-1 protease was purified and refolded from E. coli inclusion bodies.
Name:
HIV-1 Protease Mutant (V82F/I84V)
Synonyms:
n/a
Type:
Protein Complex
Mol. Mass.:
n/a
Description:
n/a
Components:
This complex has 2 components.
Component 1
Name:
HIV-1 Protease Mutant (V82F/I84V) chain A
Synonyms:
HIV-1 Protease Mutant (V82F/I84V) chain B
Type:
Enzyme Subunit
Mol. Mass.:
10816.23
Organism:
Human immunodeficiency virus type 1
Description:
Using plasmid-encoded mutant protease (Q7K/L33I/L63I designed to remove three hypersensitive autolytic sites) for the stability of protease.
Residue:
99
Sequence:
PQVTLWKRPLVTIKIGGQLKEALLDTGADDTVIEEMSLPGRWKPKMIGGIGGFIKVRQYDQIIIEICGHKAIGTVLVGPTPFNVIGRNLLTQIGCTLNF
  
Component 2
Name:
HIV-1 Protease Mutant (V82F/I84V) chain A
Synonyms:
HIV-1 Protease Mutant (V82F/I84V) chain B
Type:
Enzyme Subunit
Mol. Mass.:
10816.23
Organism:
Human immunodeficiency virus type 1
Description:
Using plasmid-encoded mutant protease (Q7K/L33I/L63I designed to remove three hypersensitive autolytic sites) for the stability of protease.
Residue:
99
Sequence:
PQVTLWKRPLVTIKIGGQLKEALLDTGADDTVIEEMSLPGRWKPKMIGGIGGFIKVRQYDQIIIEICGHKAIGTVLVGPTPFNVIGRNLLTQIGCTLNF
  
Syringe React
Source:
Purified from commercial capsules
Prep. Method:
Further purified by HPLC using a semipreparative C-18 reversed-phase column developed with 0-100% acetonitrile in 0.05% TFA
Name:
BDBM517
Synonyms:
Crixivan | CHEMBL115 | L-735, 524 | MK639 | Indinavir, 19 | (2S)-1-[(2S,4R)-4-benzyl-2-hydroxy-4-{[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]carbamoyl}butyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide | INDINAVIR SULFATE | Indinavir
Type:
Small organic molecule
Emp. Form.:
TBD
Mol. Mass.:
TBD
SMILES:
TBD
Structure:
Search PDB for entries with ligand similarity: